These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Cutaneous melanoma. II. Proposal of a new prognostic parameter: evaluation of neoplastic angiogenesis]. Marasà L; Tomasino RM Pathologica; 1983; 75(1037):353-65. PubMed ID: 6196711 [No Abstract] [Full Text] [Related]
24. Angiogenesis in melanoma. Mahabeleshwar GH; Byzova TV Semin Oncol; 2007 Dec; 34(6):555-65. PubMed ID: 18083379 [TBL] [Abstract][Full Text] [Related]
25. Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry. Liu R; Cao Z; Tu J; Pan Y; Shang B; Zhang G; Bao M; Zhang S; Yang P; Zhou Q Pigment Cell Melanoma Res; 2012 Sep; 25(5):630-8. PubMed ID: 22781316 [TBL] [Abstract][Full Text] [Related]
26. Molecular targets in melanoma from angiogenesis to apoptosis. Sosman JA; Puzanov I Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2376s-2383s. PubMed ID: 16609062 [TBL] [Abstract][Full Text] [Related]
27. [Antivascular strategies--a new concept for diagnosis and therapy of head and neck cancer. A review]. Dellian M; Eichhorn ME; Strieth S Laryngorhinootologie; 2002 Jul; 81(7):509-15. PubMed ID: 12173062 [TBL] [Abstract][Full Text] [Related]
28. Angiogenesis and lymphangiogenesis of skin cancers. Dadras SS; Detmar M Hematol Oncol Clin North Am; 2004 Oct; 18(5):1059-70, viii. PubMed ID: 15474335 [TBL] [Abstract][Full Text] [Related]
29. In vivo and in vitro evaluation of erianin, a novel anti-angiogenic agent. Gong YQ; Fan Y; Wu DZ; Yang H; Hu ZB; Wang ZT Eur J Cancer; 2004 Jul; 40(10):1554-65. PubMed ID: 15196540 [TBL] [Abstract][Full Text] [Related]
31. Current development status of small-molecule vascular disrupting agents. Chaplin DJ; Horsman MR; Siemann DW Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022 [TBL] [Abstract][Full Text] [Related]
32. Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future? Lorigan P; Eisen T; Hauschild A Exp Dermatol; 2008 May; 17(5):383-94. PubMed ID: 18312390 [TBL] [Abstract][Full Text] [Related]
33. Molecularly targeted therapy for melanoma: current reality and future options. Becker JC; Kirkwood JM; Agarwala SS; Dummer R; Schrama D; Hauschild A Cancer; 2006 Nov; 107(10):2317-27. PubMed ID: 17039502 [TBL] [Abstract][Full Text] [Related]
34. Design and development of polymer conjugates as anti-angiogenic agents. Segal E; Satchi-Fainaro R Adv Drug Deliv Rev; 2009 Nov; 61(13):1159-76. PubMed ID: 19699248 [TBL] [Abstract][Full Text] [Related]
35. Angiogenesis in malignant glioma--a target for antitumor therapy? Tuettenberg J; Friedel C; Vajkoczy P Crit Rev Oncol Hematol; 2006 Sep; 59(3):181-93. PubMed ID: 16860996 [TBL] [Abstract][Full Text] [Related]
36. Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination. Hendrix MJ; Seftor RE; Seftor EA; Gruman LM; Lee LM; Nickoloff BJ; Miele L; Sheriff DD; Schatteman GC Cancer Res; 2002 Feb; 62(3):665-8. PubMed ID: 11830517 [TBL] [Abstract][Full Text] [Related]
37. The systemic treatment of advanced cutaneous melanoma. Logan TF Facial Plast Surg Clin North Am; 2003 Feb; 11(1):75-85. PubMed ID: 15062290 [No Abstract] [Full Text] [Related]
38. Anti-angiogenic strategies for cancer therapy (Review). Benouchan M; Colombo BM Int J Oncol; 2005 Aug; 27(2):563-71. PubMed ID: 16010440 [TBL] [Abstract][Full Text] [Related]
39. Low-molecular-weight heparins and angiogenesis. Norrby K APMIS; 2006 Feb; 114(2):79-102. PubMed ID: 16519745 [TBL] [Abstract][Full Text] [Related]